This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de Olink Holding

Salud financiera controles de criterios 6/6

Olink Holding tiene un patrimonio de los accionistas total de $461.6M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $543.0M y $81.3M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$109.28m
Patrimonio	US$461.63m
Total pasivo	US$81.33m
Activos totales	US$542.96m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($221.1M) de 6XA superan a sus pasivos a corto plazo ($39.5M).

Pasivo a largo plazo: Los activos a corto plazo de 6XA ($221.1M) superan a sus pasivos a largo plazo ($41.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 6XA está libre de deudas.

Reducción de la deuda: 6XA no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 6XA tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 6XA dispone de suficiente cash runway para 2.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 13.1% cada año.

This company listing is no longer active

Salud financiera de hoja de balance de Olink Holding

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite Index

Forecast breakeven date moved forward to 2024

Olink Holding AB (publ)(NasdaqGM:OLK) dropped from S&P Global BMI Index

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute Confidence

Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023)

Forecast breakeven date pushed back to 2025

Full year 2023 earnings released: US$0.25 loss per share (vs US$0.11 loss in FY 2022)

Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024

Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development Officer

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.011 loss in 3Q 2022)

Olink Holding AB (publ) to Report Q3, 2023 Results on Nov 15, 2023

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Olink Holding AB (publ) Demonstrates the Power of the Olink Explore Platform for Driving Impactful Proteogenomic Studies At the Population Scale

Olink Holding AB (Publ) Announces the Introduction of Olink(R) Target 48 Mouse Cytokine Panel

Forecast breakeven date moved forward to 2024

Olink Holding AB (Publ) Reiterates Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.067 loss per share (vs US$0.04 loss in 2Q 2022)

Olink Holding AB (publ) to Report Q2, 2023 Results on Aug 09, 2023

Olink Holding AB (Publ) Announces the Introduction of Olink(R) Explore Ht

Now 21% undervalued

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.10 loss in 1Q 2022)

Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2023

Now 24% undervalued after recent price drop

Forecast to breakeven in 2024

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.43 loss in FY 2021)

Now 20% undervalued

Olink Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Now 22% undervalued

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.046 loss in 3Q 2021)

High number of new and inexperienced directors

Olink® Flex, A New, Unique and Fully Flexible Low-Plex Proteomics Solution Using Absolute Quantification

Third quarter 2022 earnings released: US$0.01 loss per share (vs US$0.046 loss in 3Q 2021)

Olink Holding AB (publ) Provides Earnings Guidance for the Full Year 2022

Olink Holding AB (Publ) Announces the Launch of Olink(R) Insight

Olink Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Olink Holding AB (Publ) Announces Management Appointments

Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.089 loss in 2Q 2021)

Olink Holding AB (Publ) Provides Revenue Guidance for the Fiscal Year 2022

Olink Holding AB (publ) to Report Q2, 2022 Results on Aug 11, 2022

Release of Olink Analyze 3.1 Streamlines Proteomic Analysis to Connect Data to Biological Insight

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.48 loss in 1Q 2021)

Olink Holding AB (publ) Provides Revenue Guidance for the Year 2022

Forecast breakeven date moved forward to 2023

High number of new and inexperienced directors

Olink Holding AB (publ) to Report Q1, 2022 Results on May 12, 2022

Forecast to breakeven in 2024

Olink Holding AB (publ) Announces Board Appointments

Olink Holding AB (publ) Provides Revenue Guidance for 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Olink Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2022

High number of new and inexperienced directors

Olink Holding AB (Publ) Announces Delivery of Olink® Explore 3072 Is Now Starting

Olink Holding AB (publ) Announces Delivery of Olink® Signature Q100

Third quarter 2021 earnings released: US$0.046 loss per share

Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021

Olink Holding AB (publ) Announces UK Biobank Pharma Proteomics Project's Expansion of Ongoing Proteomics Study Of 53,000 Participants to the New Olink Explore 3072 Platform

Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million.

Olink Holding AB (publ) Provides Preliminary Unaudited Earnings Guidance for the Second Quarter Ended June 30, 2021

Olink Announces the New Explore 3072 High Throughput Proteomics Platform

SCALLOP Launches Clinical Trial Arm to Uncover Next Level of Drug Target Insights from Proteomic Profiling

Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021

Olink Announces First Core Lab Running the Olink Explore Platform in Europe, Making It Available for More Researchers

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera